Discriminating factors between responder and non-responder in infliximab-treated patients with rheumatoid arthritis

• Published in: Nihon Rinsho Men'eki Gakkai Sokai Shorokushu Vol. 35; p. 75
• Main Authors: 亀田, 秀人, 奥山, あゆみ, 津坂, 憲政, 関口, 直哉, 竹内, 勤, 鈴木, 勝也, 天野, 宏一, 長澤, 逸人, 西, 英子, 武井, 博文
• Format: Journal Article
• Language: Japanese
• Published: 日本臨床免疫学会 2007; The Japan Society for Clinical Immunology
• Subjects: infliximab; interleukin-6; responder; rheumatoid arthritis; tumor necrosis factor alpha
• ISSN: 1880-3296
• DOI: 10.14906/jscisho.35.0.75.0

Objective.To examine whether responder could be discriminated in RA patients receiving infliximab.Methods. ACR improvement criteria and EULAR responses by Disease Activity Score (DAS) 28-4 (crp) were used to evaluate 99 patients with RA who received infliximab in Saitama Medical Center. We considered patients as responder if they fulfilled at least ACR 70 or EULAR remission at 30 weeks. Whole blood drawn from patients before using infliximab was stimulated by LPS for cytokines production. Demographic data and cytokines were used for multivariable analysis. Result.Demographic data were insufficient for discrimination between responder and non-responder, however, if added cytokines, especially tumor necrosis factor alpha and interleukin-6, on to it, 87.8% of responders were discriminated.Conclusion.Not only demographic data but also cytokines were necessary for responder discrimination.